Human Enhancement Freaks People Out, Study Finds; Designer Babies Might 'Meddle With Nature'
By Ed Cara,
Medical Daily
| 07. 26. 2016
Fond as we are of superheroes on the big screen, most of us would stop short of actually becoming one via technology.
That’s the verdict issued by an extensive survey conducted by the Pew Research Center and released Tuesday. The Center polled over 4,000 Americans on a variety of issues related to advances in biomedical technology that may arrive in the near future — from using implanted brain chips to boost our thinking power to editing the genes of babies to eliminate hereditary flaws and diseases. The representative sample of Americans proved to be more careful than celebratory about these technological leaps.
Sixty-eight percent were somewhat or very worried about gene-editing, as opposed to 49 percent who saw themselves as at least somewhat enthusiastic about the prospect. Sixty-nine percent were also wary of brain implants and 63 percent felt the same about using synthetic blood transfusions to improve our strength, speed, and stamina. A similar percentage were taken aback at the thought of trying these technologies out on themselves or their future children.
"Developments in biomedical technologies are accelerating rapidly, raising...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...